Interestingly, the TP53 R allele patients with pathogenic somatic mtDNA mutations demonstrated a significant association with a poorer DFS than other patients (HR = 1.71; 95% CI, 1.15–2.57; p = 0.009; Figure 2E, Table 4) and this phenomenon still existed after adjusting for mtDNA haplogroup, tumor stage with treatment regimens, differentiation and age at diagnosis (HR = 1.59; 95% CI, 1.06–2.40; p = 0.03; Table 4). Here, TP53 is linked to neoplasm.